Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7408684rdf:typepubmed:Citationlld:pubmed
pubmed-article:7408684lifeskim:mentionsumls-concept:C0341628lld:lifeskim
pubmed-article:7408684lifeskim:mentionsumls-concept:C0013072lld:lifeskim
pubmed-article:7408684lifeskim:mentionsumls-concept:C0010068lld:lifeskim
pubmed-article:7408684lifeskim:mentionsumls-concept:C0000946lld:lifeskim
pubmed-article:7408684pubmed:issue27lld:pubmed
pubmed-article:7408684pubmed:dateCreated1980-11-20lld:pubmed
pubmed-article:7408684pubmed:abstractTextIn 20 patients with coronary heart disease and typical changes in the exercise ECG (evidence of myocardial hypoxia), which disappeared completely on second ergometry after isosorbid dinitrate, the effect of a single dose of 400 mg acebutolol (Prent) was tested on exercise. Ergometrically induced cardiac work was significantly reduced in all patients, compared with leg exercise (little change in lower, more marked change in the higher ranges of exercise) so that repeat ergometry at the same ergometric level of exercise produced neither signs of hypoxia nor angina. There were no significant changes after a placebo.lld:pubmed
pubmed-article:7408684pubmed:languagegerlld:pubmed
pubmed-article:7408684pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7408684pubmed:citationSubsetIMlld:pubmed
pubmed-article:7408684pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7408684pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7408684pubmed:statusMEDLINElld:pubmed
pubmed-article:7408684pubmed:monthJullld:pubmed
pubmed-article:7408684pubmed:issn0012-0472lld:pubmed
pubmed-article:7408684pubmed:authorpubmed-author:LudwigBBlld:pubmed
pubmed-article:7408684pubmed:authorpubmed-author:BöhmHHlld:pubmed
pubmed-article:7408684pubmed:issnTypePrintlld:pubmed
pubmed-article:7408684pubmed:day4lld:pubmed
pubmed-article:7408684pubmed:volume105lld:pubmed
pubmed-article:7408684pubmed:ownerNLMlld:pubmed
pubmed-article:7408684pubmed:authorsCompleteYlld:pubmed
pubmed-article:7408684pubmed:pagination958-60lld:pubmed
pubmed-article:7408684pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:meshHeadingpubmed-meshheading:7408684-...lld:pubmed
pubmed-article:7408684pubmed:year1980lld:pubmed
pubmed-article:7408684pubmed:articleTitle[Acebutolol in coronary heart disease: an ergometric double-blind study (author's transl)].lld:pubmed
pubmed-article:7408684pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7408684pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7408684pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:7408684pubmed:publicationTypeRandomized Controlled Triallld:pubmed